It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IART’s FA Score shows that 1 FA rating(s) are green whileOSUR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IART’s TA Score shows that 5 TA indicator(s) are bullish while OSUR’s TA Score has 5 bullish TA indicator(s).
IART (@Medical/Nursing Services) experienced а +5.28% price change this week, while OSUR (@Pharmaceuticals: Other) price change was -7.64% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.47%. For the same industry, the average monthly price growth was -1.93%, and the average quarterly price growth was +3.55%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.70%. For the same industry, the average monthly price growth was -2.56%, and the average quarterly price growth was +2.10%.
IART is expected to report earnings on Oct 29, 2025.
OSUR is expected to report earnings on Nov 05, 2025.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+2.70% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
IART | OSUR | IART / OSUR | |
Capitalization | 1.01B | 203M | 498% |
EBITDA | -332.17M | -28.02M | 1,185% |
Gain YTD | -42.857 | -22.992 | 186% |
P/E Ratio | 66.48 | 26.67 | 249% |
Revenue | 1.62B | 162M | 1,001% |
Total Cash | 254M | 248M | 102% |
Total Debt | 2.01B | 14.2M | 14,183% |
IART | OSUR | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 94 | |
PRICE GROWTH RATING 1..100 | 64 | 64 | |
P/E GROWTH RATING 1..100 | 9 | 6 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OSUR's Valuation (67) in the Medical Specialties industry is in the same range as IART (80). This means that OSUR’s stock grew similarly to IART’s over the last 12 months.
OSUR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IART (100). This means that OSUR’s stock grew similarly to IART’s over the last 12 months.
OSUR's SMR Rating (94) in the Medical Specialties industry is in the same range as IART (97). This means that OSUR’s stock grew similarly to IART’s over the last 12 months.
OSUR's Price Growth Rating (64) in the Medical Specialties industry is in the same range as IART (64). This means that OSUR’s stock grew similarly to IART’s over the last 12 months.
OSUR's P/E Growth Rating (6) in the Medical Specialties industry is in the same range as IART (9). This means that OSUR’s stock grew similarly to IART’s over the last 12 months.
IART | OSUR | |
---|---|---|
RSI ODDS (%) | N/A | 3 days ago80% |
Stochastic ODDS (%) | 3 days ago75% | 3 days ago71% |
Momentum ODDS (%) | 3 days ago69% | 3 days ago79% |
MACD ODDS (%) | 3 days ago70% | 3 days ago77% |
TrendWeek ODDS (%) | 3 days ago60% | 3 days ago79% |
TrendMonth ODDS (%) | 3 days ago74% | 3 days ago80% |
Advances ODDS (%) | 3 days ago59% | 17 days ago73% |
Declines ODDS (%) | 12 days ago76% | 4 days ago80% |
BollingerBands ODDS (%) | 3 days ago65% | 3 days ago81% |
Aroon ODDS (%) | N/A | 3 days ago69% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FITLX | 28.23 | 0.19 | +0.68% |
Fidelity U.S. Sustainability Index | |||
GGZPX | 23.83 | 0.16 | +0.68% |
Goldman Sachs Enhanced U.S. Equity P | |||
PJHRX | 28.66 | 0.12 | +0.42% |
PGIM Jennison Health Sciences R | |||
PVETX | 16.87 | N/A | N/A |
PACE Small/Medium Co Val Eq P2 | |||
MMBUX | 11.09 | -0.04 | -0.36% |
MassMutual Select TRP Sm&Mid Cap Blend I |
A.I.dvisor indicates that over the last year, IART has been loosely correlated with ENOV. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if IART jumps, then ENOV could also see price increases.
Ticker / NAME | Correlation To IART | 1D Price Change % | ||
---|---|---|---|---|
IART | 100% | +2.61% | ||
ENOV - IART | 58% Loosely correlated | -0.28% | ||
CNMD - IART | 50% Loosely correlated | +2.42% | ||
RVTY - IART | 49% Loosely correlated | +0.44% | ||
ZBH - IART | 46% Loosely correlated | +0.84% | ||
TMCI - IART | 45% Loosely correlated | +7.92% | ||
More |